Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN.

Mutant p53 exerts gain-of-function effects that drive metastatic progression and therapeutic resistance, but the basis for these effects remain obscure. The RNA binding protein RBM38 limits translation of mutant p53 and is often altered in tumors harboring it. Here we show how loss of Rbm38 significantly alters cancer susceptibility in mutant p53 knock-in mice by shortening lifespan, altering tumor incidence, and promoting T-cell lymphomagenesis. Loss of Rbm38 enhanced mutant p53 expression and decreased expression of the tumor suppressor Pten, a key regulator of T-cell development. Furthermore, Rbm38 was required for Pten expression via stabilization of Pten mRNA through an AU-rich element in its 3'UTR. Our results suggest that Rbm38 controls T-cell lymphomagenesis by jointly modulating mutant p53 and Pten, with possible therapeutic implications for treating T-cell malignancies.Significance: An RNA-binding protein controls T-cell lymphomagenesis by jointly modulating mutant p53 and PTEN, with possible therapeutic implications for treating T-cell malignancies. Cancer Res; 78(6); 1511-21. ©2018 AACR.

[1]  Seong-Jun Cho,et al.  Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner , 2017, Proceedings of the National Academy of Sciences.

[2]  J. Tuscano,et al.  The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity , 2016, Cancer Immunology, Immunotherapy.

[3]  X. Miao,et al.  Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy , 2016, Chemotherapy.

[4]  B. Torbett,et al.  The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation. , 2016, Leukemia research.

[5]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[6]  Min Zhang,et al.  PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38 , 2015, Oncogene.

[7]  R. Cardiff,et al.  Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors , 2014, Proceedings of the National Academy of Sciences.

[8]  Chang S. Chan,et al.  The evolution of thymic lymphomas in p53 knockout mice , 2014, Genes & development.

[9]  Wenbin Zhou,et al.  RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer , 2014, BMC Cancer.

[10]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[11]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[12]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[13]  Seong-Jun Cho,et al.  Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1 , 2013, Genes & development.

[14]  Xinbin Chen,et al.  Regulation of Mdm2 mRNA Stability by RNA-binding Protein RNPC1 , 2013, Oncotarget.

[15]  L. Attardi,et al.  Not all p53 gain-of-function mutants are created equal , 2013, Cell Death and Differentiation.

[16]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[17]  Xinbin Chen,et al.  MDM2 Expression Is Repressed by The RNA-Binding Protein RNPC1 via mRNA Stability , 2012, Oncogene.

[18]  J. Ule,et al.  Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity , 2011, Nature communications.

[19]  Ferdinando Di Cunto,et al.  Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs , 2011, Cell.

[20]  Seong-Jun Cho,et al.  Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. , 2011, Genes & development.

[21]  Yu Huang,et al.  MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. , 2010, International journal of molecular medicine.

[22]  Jin Zhang,et al.  The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability , 2010, Nucleic Acids Res..

[23]  W. Pear,et al.  Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. , 2010, The Journal of clinical investigation.

[24]  Xinbin Chen,et al.  RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability , 2010, Proceedings of the National Academy of Sciences.

[25]  Patrick J. Paddison,et al.  Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia , 2010, Nature Cell Biology.

[26]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[27]  Takayuki Morisaki,et al.  RNA‐binding proteins Rbm38 and Rbm24 regulate myogenic differentiation via p21‐dependent and ‐independent regulatory pathways , 2009, Genes to cells : devoted to molecular & cellular mechanisms.

[28]  L. Chin,et al.  High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. , 2009, Blood.

[29]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[30]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[31]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[32]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[33]  Wensheng Yan,et al.  RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. , 2006, Genes & development.

[34]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[35]  F. Macian,et al.  NFAT proteins: key regulators of T-cell development and function , 2005, Nature Reviews Immunology.

[36]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[37]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[38]  X. Chen,et al.  The common and distinct target genes of the p53 family transcription factors , 2004, Cellular and Molecular Life Sciences CMLS.

[39]  Xinbin Chen,et al.  Isolation and Characterization of Fourteen Novel Putative and Nine Known Target Genes of the p53 Family , 2003, Cancer biology & therapy.

[40]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[41]  A. Sher,et al.  T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Xinbin Chen,et al.  p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes , 2001, Oncogene.

[43]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[44]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[45]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[46]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[47]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[48]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[49]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[50]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[51]  R. Weinmann,et al.  Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. , 1986, The Journal of biological chemistry.

[52]  王莹,et al.  Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer. , 2015 .

[53]  Beth Israel,et al.  Decision letter: Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010 .

[54]  M. Dohn,et al.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. , 2001, Oncogene.

[55]  L. Glimcher,et al.  NFATc1 and NFATc2 together control both T and B cell activation and differentiation. , 2001, Immunity.

[56]  A. Sher,et al.  T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Crabtree,et al.  The transcription factor NF-ATc1 regulates lymphocyte proliferation and Th2 cytokine production. , 1998, Immunity.

[58]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.